Celgene Corporation on August 27, 2015 announced that it has closed the $7.2 billion deal to acquire Receptos Inc. The acquisition of Receptos significantly enhances Celgene’s inflammation & immunology (I&I) portfolio, further diversifies the company's expected revenue beginning in 2019, and builds upon Celgene’s growing expertise in inflammatory bowel disease (IBD).
"The Receptos acquisition provides a transformational opportunity for Celgene to impact multiple therapeutic areas. This acquisition enhances our inflammation & immunology portfolio and allows us to leverage the investments made in our global organisation to accelerate our growth in the medium and long-term,” said Bob Hugin, chairman and chief executive officer of Celgene.
The transaction also adds Ozanimod, a novel, potential best-in-class, oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator (S1P) to Celgene’s diverse pipeline of potential disease-altering medicines and investigational compounds. Based on clinical studies, Ozanimod demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), including its cardiac, hepatotoxicity and lymphocyte recovery profile. Additionally, Celgene believes Ozanimod is positioned to potentially become the first S1P receptor modulator to be approved for IBD.
"The Receptos acquisition provides a transformational opportunity for Celgene to impact multiple therapeutic areas. This acquisition enhances our inflammation & immunology portfolio and allows us to leverage the investments made in our global organisation to accelerate our growth in the medium and long-term,” said Bob Hugin, chairman and chief executive officer of Celgene.
The transaction also adds Ozanimod, a novel, potential best-in-class, oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator (S1P) to Celgene’s diverse pipeline of potential disease-altering medicines and investigational compounds. Based on clinical studies, Ozanimod demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), including its cardiac, hepatotoxicity and lymphocyte recovery profile. Additionally, Celgene believes Ozanimod is positioned to potentially become the first S1P receptor modulator to be approved for IBD.